Liang W, Ding P, Li G, Lu E, Zhao Z. Drug Des Devel Ther. 2021;15:905–917.
The authors have advised Figure 3 on page 911 is incorrect. Due to an error at the time of figure assembly part of the 25 μg/ml and 100 μg/ml groups in figure part D were duplicated. The correct Figure 3 is shown below.
Figure 3.
The effects of nHAP on the viability and osteoblast differentiation of SuSCs. (A) SuSCs were exposed to various concentrations of nHAP (0, 25, 50 and 100 μg/mL) for 48h. Live/dead staining was applied to assess the cytotoxicity of nHAP. Scale bar, 100 μm. (B) CCK-8 analysis evaluates the viability of SuSCs treated with nHAP in different concentrations at 24 h, and (C) 48 h. (D) The extracellular calcium deposition was visualized by Alizarin Red S staining after cells were cultured with nHAP in different concentrations for 14 days; scale bar, 100 μm. (E) Mineralization was quantified following the colorimetric analysis of Alizarin Red S elution from calcium nodules. The expression level of osteoblastogenic genes (F) alp, (G) runx2 and (H) col1 in the presence of various concentrations of nHAP. *p < 0.05, **p < 0.01, ***p < 0.001. (I) The expression of osteoblast-associated proteins (col1, runx2, osteopontin) under nHAP treatment was assessed.
The authors apologize for this error and advise it does not affect the results of the paper.